Gluz, O., Nitz, U. A., Christgen, M., Kuemmel, S., Holtschmidt, J., Schumacher, J., Raeth, P., Hartkopf, A. D., Luedtke-Heckenkamp, K., Just, M., Schumann, R. V., Polata, S., Schinkoethe, T., Graeser, M. K., Kates, R., Wuerstlein, R., Harbeck, N. (2026). Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-01047